We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
- Authors
Pozo-Rosich, Patricia; Ashina, Messoud; Tepper, Stewart J.; Jensen, Sidsel; Boserup, Line Pickering; Josiassen, Mette Krog; Sperling, Bjørn
- Abstract
Introduction: In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER study in subgroups defined by prior treatment failure type. Methods: DELIVER (NCT04418765) randomized adults with migraine to eptinezumab 100 mg, 300 mg, or placebo, administered intravenously every 12 weeks. Changes from baseline in MMDs and percentages of patients with ≥ 50% reduction from baseline in MMDs (≥ 50% migraine responder rates [MRRs]) were summarized in subgroups of patients defined by prior treatment failure type. Subgroups were not mutually exclusive and included patients for whom topiramate, beta blockers (metoprolol, propranolol), amitriptyline, and/or flunarizine had failed. Results: Across Weeks 1–12 in all subgroups, patients treated with eptinezumab experienced greater reductions from baseline in MMDs than those receiving placebo (reductions ranged from 4.5–5.5 vs 1.6–2.4, respectively), with larger reductions over Weeks 13–24. Similarly, ≥ 50% MRRs were consistently higher with eptinezumab than placebo and increased following a second infusion. Conclusion: In all subgroups, regardless of prior preventive treatment failure type, eptinezumab demonstrated greater reductions in MMDs and higher MRRs compared with placebo. Trial Registration: ClinicalTrials.gov (Identifier: NCT04418765).
- Subjects
TREATMENT failure; MIGRAINE; AMITRIPTYLINE; PLACEBOS; PROPRANOLOL
- Publication
Neurology & Therapy, 2024, Vol 13, Issue 2, p339
- ISSN
2193-8253
- Publication type
Article
- DOI
10.1007/s40120-023-00575-5